Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours

NCT04544995 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04544995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04544995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Terminated
Start date
October 6, 2020
Completion date
April 23, 2025
Enrollment
47 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms